NeoGraph Analytics
PharmaceuticalsGlobal2026 – 2032

Vaccine Cold Chain Market Size, Share & Forecast 2026-2032

Vaccine cold chain at $37.78B in 2026 reaching $56.8B by 2032 at 7.03% CAGR. Published 2025 sizings span 11.2x; UNICEF's 2.787bn doses test every one of them.

Revenue, 2026

$37.8B

Forecast, 2032

$56.8B

CAGR, 2026-2032

7.03%

Report Coverage

Global

Code: vaccine-cold-chain-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Vaccine cold chain is the worst-measured market in this corpus. Published 2025 sizings run from $4.13 billion to a derived $46.35 billion, an 11.2x spread, and stated growth rates from 0.85% to 10.23%, a 12.0x spread in the rate - extreme on both dimensions at once. One publisher disagrees with itself: IMARC prints vaccine storage and packaging at $35.3 billion growing at 7.03% and healthcare cold chain logistics at $18.1 billion growing at 2.8%. The buyer side settles more than the supplier side can. UNICEF, the largest single vaccine buyer in the world, delivered 2.787 billion doses to 99 countries in 2024 and spent $5.610 billion on all procurement across 160 countries, supplies and services and vaccines included. The derived $46.35 billion vaccine cold chain is therefore 8.26 times UNICEF's entire budget, and IMARC's $35.3 billion is 6.29 times it. Dividing each published market by UNICEF's dose volume gives $1.48, $12.67 and $16.63 of cold chain cost per dose; even assuming a global volume of 6 billion doses the larger two still imply $5.88 and $7.73, against routine antigen prices measured in cents to a few dollars. Only the logistics-only figure is plausible as the cost of moving a dose. We publish IMARC's storage-and-packaging series, which is the most completely disclosed scope in the set, rebased to 2026 at its own stated rate - and we publish the stated rate rather than the stated endpoint, because 35.3 x 1.0703^9 = 65.01 against a published 66.3 billion.

02

Key Highlights

1

Published 2025 sizings span 11.2x ($4.13 billion to a derived $46.35 billion) and stated growth rates span 12.0x (0.85% to 10.23%) - extreme disagreement on both dimensions at once

2

UNICEF delivered 2.787 billion vaccine doses to 99 countries in 2024 on total procurement of $5.610 billion, which makes the derived $46.35 billion vaccine cold chain 8.26 times the entire budget of the world's largest vaccine buyer

3

Dividing the published markets by UNICEF's dose volume gives $1.48, $12.67 and $16.63 per dose; only the first is plausible as the cost of moving and storing a routine immunisation dose

4

IMARC's series fails its own arithmetic: 35.3 x 1.0703^9 = 65.01 against a published $66.3 billion endpoint, which implies 7.26% rather than the stated 7.03%

5

The sector's only listed pure-play, Cryoport, had total 2025 revenue of $176.2 million - 4.3% of even the smaller published market - and its growth came from cell and gene therapy, not vaccines

6

WHO's prequalified immunization device catalogue cannot be used as a count: its own guidance states references are never reassigned, so retired products leave permanent gaps in the numbering

03

Market Overview

Market Context

Vaccine cold chain is a cost centre inside a system funded by donors and ministries of health, not a market with a price-setting mechanism of its own. UNICEF, Gavi and PAHO buy most of the doses that move through it, publish awarded prices per antigen, and tender the logistics; the result is that the ceiling on cold chain spend per dose is set by what a public immunisation budget can bear, not by what the service is worth. That is why the growth rates in this sector have diverged so sharply from the rest of healthcare logistics. The money in temperature-controlled life science supply has moved to cell and gene therapy, where a single shipment can be worth more than a million doses of measles vaccine - Cryoport's commercial cell and gene therapy revenue grew 29% in 2025 while the vaccine-specific logistics market is forecast at under 1% a year. The ultra-cold capacity built for mRNA COVID vaccines is now serving that higher-value traffic. Vaccine cold chain inherits the installed base and keeps the volume, but not the pricing power.

Vaccine cold chain carries the widest published disagreement in this corpus on both dimensions at once. For 2025 the estimates run from $4.13 billion to a derived $46.35 billion, an 11.2x spread, and the stated growth rates run from 0.85% to 10.23%, a 12.0x spread in the rate itself. One publisher disagrees with itself by almost two to one. UNICEF settles part of it: it delivered 2.787 billion vaccine doses to 99 countries in 2024 and spent $5.610 billion on all procurement across 160 countries, so a $46.35 billion vaccine cold chain is 8.26 times the entire budget of the world's largest vaccine buyer, including the vaccines. Dividing the published markets by UNICEF's dose volume gives $1.48, $12.67 and $16.63 per dose. Only the first is plausible as the cost of moving a dose; the larger figures are defensible only as equipment plus packaging plus services, which is what the publisher we follow says it counts.

Market Stage

Mature

Adoption Level

Universal and mandatory for licensed vaccines; the constraint is last-mile equipment and monitoring in low-income settings

Key Trends

The spread is extreme on both dimensions simultaneously: 11.2x in base-year size ($4.13 billion to a derived $46.35 billion for 2025) and 12.0x in stated growth rate (0.85% to 10.23%)Equipment versus movement is the scope line that explains it: a refrigerator is capital equipment with a ten-year life while shipping a dose is a service consumed once, and the 8.5x gap between the two main readings is almost entirely hardware and packagingCOVID normalisation is why the logistics-only reading prints 0.85%: Roots Analysis segments explicitly by COVID-19 versus other vaccines, and a logistics market inflated by the COVID campaign shrinks back toward routine immunisation volumes from a 2025 baseThe growth in temperature-controlled life science logistics has moved to cell and gene therapy, not vaccines: Cryoport, the sector's only listed pure-play, grew commercial cell and gene therapy support 29% to $33.4 million in 2025 on total revenue of $176.2 millionOne publisher's own series fails its own arithmetic: IMARC states $35.3 billion for 2025, $66.3 billion for 2034 and a 7.03% CAGR, but 35.3 x 1.0703^9 = 65.01 and the endpoint implies 7.26%WHO's prequalified immunization device catalogue cannot be counted from its product codes: its own guidance states a reference is never reassigned, so breaks in the numerical sequence appear when an item is dropped
04

Market Forecast & Data

Market Growth Forecast
2026-2032 · CAGR 7.03%

Base Year (2026)

$37.8B

Forecast (2032)

$56.8B

CAGR (2026-2032)

7.03%

Market size by year, 2026-2032, in USD Billion.
YearMarket size ($ Billion)
2026Base year$37.78B
2027$40.44B
2028$43.28B
2029$46.33B
2030$49.59B
2031$53.08B
2032$56.80B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

We publish 7.03%, which is IMARC's own stated rate for its vaccine storage and packaging scope, and we deliberately prefer the rate to the publisher's own endpoint because the two do not reconcile: 35.3 x 1.0703^9 gives $65.01 billion against a published $66.3 billion for 2034, an implied 7.26%. Advancing the 2025 base one year gives 35.3 x 1.0703 = $37.78 billion for 2026, and interpolating on the same rate gives 37.78 x 1.0703^6 = $56.80 billion for 2032, inside the publisher's series rather than at its endpoint. The 7.03% rate sits between the two bounding readings for a defensible reason. The 0.85% logistics-only rate reflects COVID normalisation in a service consumed once per dose; the 10.23% whole-healthcare rate reflects cell and gene therapy growth that has nothing to do with vaccines. An equipment-weighted vaccine market should grow faster than the first, because installed hardware generates replacement demand on a service-life cycle independent of dose volumes, and slower than the second, because none of the high-value cell and gene traffic is in its scope. What the rate does not price is whether donor immunisation budgets grow at all, which is the actual determinant and is political.

05

Market Dynamics

  • Routine immunisation volume is enormous and non-discretionary: UNICEF alone delivered 2.787 billion doses to 99 countries in 2024, stated as enough to reach 45% of the world's children under five
  • Ultra-cold and cryogenic capability built for mRNA COVID vaccines is now installed capacity that serves cell and gene therapy and clinical trial logistics, which is where Cryoport's growth came from in 2025
  • Equipment replacement rather than new installation drives the hardware half of the market: a prequalified vaccine refrigerator has a defined service life, so a large installed base generates recurring demand independent of dose growth
  • Temperature monitoring and data logging have shifted from optional to expected, adding a per-shipment software and device cost that did not exist a decade ago
  • Solar direct-drive refrigeration has made cold chain viable in settings without reliable grid power, expanding the equipment market into locations that previously could not hold a vaccine at all
06

Market Segmentation

By Type

  • Storage Equipment (Refrigerators, Freezers, Cold Rooms)
  • Passive Packaging (Cool Bags, Cold Boxes, Vaccine Carriers)
  • Transportation Services (Ground, Air, Ocean)
  • Warehouse Storage Services
  • Temperature Monitoring and Data Logging

By End User

  • UN Agencies and Donor-Funded Immunisation Programmes
  • National Immunisation Programmes and Ministries of Health
  • Biopharmaceutical Manufacturers
  • Hospitals and Primary Care Facilities
  • Medical Laboratories

By Application

  • Routine Childhood Immunisation
  • Outbreak and Campaign Response
  • Adult and Seasonal Influenza Vaccination
  • Clinical Trial Vaccine Supply
07

Competitive Landscape

C

Cryoport

Brentwood, Tennessee, United States

The only listed pure-play in temperature-controlled life science logistics and equipment, with total 2025 revenue of $176.2 million - about 4.3% of the smaller published vaccine cold chain market. Share is not disclosed and the business is cell-and-gene-weighted rather than vaccine-weighted.

Reports both halves of the business: Life Sciences Services at $96.497 million, up 17.6%, and Life Sciences Products at $79.680 million, up 6.6%, for FY2025. Growth came from cell and gene therapy rather than vaccines - commercial cell and gene therapy support rose 29% to a record $33.4 million and clinical trial support 14% to $47.1 million. Gross margin improved from 44.4% to 47.1% and the company guided to $190-194 million for 2026. Entered a strategic partnership with DHL Group that included DHL acquiring CRYOPDP.

T

Thermo Fisher Scientific

Waltham, Massachusetts, United States

Named among the companies covered in IMARC's vaccine storage and packaging report. Supplies laboratory and pharmacy-grade refrigeration, ultra-low temperature freezers and cryogenic storage, with no vaccine cold chain revenue line disclosed.

The largest supplier of the hardware half of this market by breadth, spanning pharmacy refrigerators, ultra-low temperature freezers built out during the mRNA COVID campaign, and cryogenic storage. Because the equipment is sold into laboratory, clinical, biobanking and vaccine applications from a single catalogue and reported inside wider segments, no vaccine-specific figure is derivable from its filings.

D

DHL Group (Life Sciences & Healthcare)

Bonn, Germany

Named among the companies covered in IMARC's report and the largest operator of temperature-controlled pharmaceutical logistics networks by footprint. No vaccine cold chain revenue line is disclosed.

Operates the global air and ground freight and certified pharmaceutical warehousing on which donor-funded vaccine delivery depends. Reinforced its position in the specialist end of the market through a strategic partnership with Cryoport and the acquisition of CRYOPDP, which consolidated one of the few remaining independent specialist couriers in the sector.

K

Kuehne+Nagel

Schindellegi, Switzerland

Major provider of pharmaceutical and healthcare air and sea freight with GDP-certified temperature-controlled facilities. Vaccine-specific revenue is not disclosed.

Competes with DHL for the lane management, airport-to-airport and bonded storage work that moves bulk vaccine consignments between manufacturer and country. Its disclosure, like DHL's, aggregates healthcare logistics into a wider division, which is the structural reason this market has no supply-side sum to test published sizings against.

E

Envirotainer

Rosersberg, Sweden

The leading supplier of active, powered air freight containers for temperature-controlled pharmaceutical shipments, operating on a lease-per-shipment model. Privately held; no revenue is disclosed.

Occupies the active-container segment that Roots Analysis separates from passive packaging. An active container holds temperature electronically through a long-haul flight and is leased rather than sold, which makes its economics per shipment rather than per unit - the clearest case in this market of a cost that scales with doses moved rather than with installed base.

B

B Medical Systems

Hosingen, Luxembourg

A specialist supplier of WHO-prequalified vaccine refrigerators, freezers and solar direct-drive units for low-resource settings. Privately held; no revenue is disclosed.

Sells into the UN and donor procurement channel that requires listing in the WHO Catalogue of Prequalified Immunization Devices, where refrigerators and freezers sit in category E003. Prequalification is the commercial moat in this segment: a product in the catalogue is procurable by UN agencies and one without it is not, regardless of its specifications.

08

Recent Developments

26
2026Cryoport

Reported fourth-quarter and full-year 2025 results on 3 March 2026: revenue of $176.2 million, above the high end of guidance and up about 12%, with Life Sciences Services at $96.497 million (+17.6%) and Life Sciences Products at $79.680 million (+6.6%); commercial cell and gene therapy support rose 29% to a record $33.4 million; gross margin improved to 47.1% from 44.4%; 2026 guidance of $190-194 million.

26
2026IMARC Group

Published a vaccine storage and packaging market of $35.3 billion for 2025 rising to $66.3 billion by 2034 at a stated 7.03% CAGR on 15 May 2026 - a series whose stated rate and stated endpoint do not reconcile, since 35.3 x 1.0703^9 gives 65.01 and the endpoint implies 7.26%.

26
2026Roots Analysis

Updated its Cold Chain Logistics Market for Vaccines report in August 2026 with a 2025 value of $4.13 billion growing at 0.85% a year to $4.32 billion by 2030, segmented explicitly by COVID-19 versus other vaccines - the lowest growth rate published for any market in this corpus.

25
2025DHL Group

Entered a strategic partnership with Cryoport that included DHL's acquisition of CRYOPDP, consolidating one of the few remaining independent specialist temperature-controlled couriers into a global logistics network.

24
2024UNICEF Supply Division

Delivered 2.787 billion vaccine doses to 99 countries, stated as enough to reach 45% of the world's children under five, on total procurement of $5.610 billion across 160 countries - $3.778 billion of supplies and $1.832 billion of services, a 7% increase on the previous year.

09

Regulatory Landscape

WHO Performance, Quality and Safety (PQS) prequalification and the WHO Catalogue of Prequalified Immunization Devices: a refrigerator, freezer, cold box or vaccine carrier must be listed in the catalogue, where refrigerators and freezers occupy category E003, to be procurable by UN agencies. The catalogue states that a product reference is never reassigned, so breaks appear in the numerical sequence when an item is dropped - which means the codes cannot be read as a count of current products.WHO Good Distribution Practices for pharmaceutical products and the EU Guidelines on Good Distribution Practice of medicinal products for human use (2013/C 343/01), which set the qualification, mapping, monitoring and excursion-management requirements that make temperature-controlled distribution a regulated activity rather than ordinary freight.WHO Vaccine Vial Monitor requirements and the controlled temperature chain framework, under which specific vaccines are licensed to tolerate defined excursions outside 2-8 degrees Celsius for a limited period - the only regulatory lever that materially reduces last-mile equipment dependence.UNICEF Supply Division tendering and long-term arrangements, which publish awarded prices per dose by antigen and set the procurement terms for the largest single vaccine buyer in the world, and therefore set the price ceiling on the logistics that serve donor-funded immunisation.IATA Temperature Control Regulations and the Perishable Cargo Regulations chapter governing time- and temperature-sensitive healthcare shipments, which determine how active and passive containers may be carried by air and are the operative rules for the lane between manufacturer and country.
10

Research Methodology

Primary research

  • Division of each published market size by UNICEF's disclosed 2024 vaccine dose volume to derive an implied cold chain cost per dose, and comparison of each against UNICEF's total procurement budget
  • Derivation of a vaccine slice of the healthcare cold chain by multiplying one publisher's whole-market total by its own stated vaccine product share, labelled as derived and used only to bound the spread

Secondary research

  • UNICEF Supply Annual Report 2024 - 2.787 billion vaccine doses delivered to 99 countries, enough to reach 45% of the world's children under five; total 2024 procurement $5.610 billion across 160 countries, of which $3.778 billion supplies and $1.832 billion services
  • Cryoport, Inc. Fourth Quarter and Full-Year 2025 Financial Results, 3 March 2026 - revenue $176.2 million, Life Sciences Services $96.497 million (+17.6%), Life Sciences Products $79.680 million (+6.6%), commercial cell and gene therapy support $33.4 million (+29%), gross margin 47.1%
  • IMARC Group, Global Vaccine Storage and Packaging Market, published 15 May 2026 - $35.3 billion (2025) to $66.3 billion (2034) at a stated 7.03% CAGR for 2026-2034, historical period 2020-2025, with disclosed equipment, packaging-type and packaging-level segmentation
  • Roots Analysis, Cold Chain Logistics Market for Vaccines: Industry Trends and Global Forecasts till 2030, last updated August 2026 - $4.13 billion (2025), $4.18 billion (2026) to $4.32 billion (2030) at 0.85%, segmented by COVID-19 versus other vaccines
  • Mordor Intelligence, Healthcare Cold Chain Market, page updated 11 September 2026 with estimates as of January 2026 - $124.53 billion (2025) to $223.39 billion (2031) at 10.23%, with vaccines stated at 37.23% of 2025 market revenue
  • WHO Catalogue of Prequalified Immunization Devices (IMD-PQS), refrigerators and freezers in category E003, edition dated 14 February 2025, including the guidance that product references are never reassigned so gaps appear in the sequence
  • IMARC Group, Global Healthcare Cold Chain Logistics Market Report and Forecast 2025-2033 - $18.1 billion (2024) to $23.2 billion (2033) at 2.8%, the same publisher's logistics-only scope

Validation: Three tests were run against countable public figures rather than against another forecast. First, each published market size was divided by UNICEF's disclosed 2024 vaccine delivery volume of 2.787 billion doses, giving an implied cold chain cost per dose of $1.48 for Roots Analysis' logistics-only figure, $12.67 for IMARC's storage-and-packaging figure and $16.63 for the vaccine slice derived from Mordor's whole-market total. Allowing a generous global dose volume of 6 billion, more than double UNICEF's, the latter two still imply $5.88 and $7.73 per dose. Second, and decisively, the derived $46.35 billion vaccine cold chain figure was compared with UNICEF's total 2024 procurement of $5.610 billion, which covered all supplies and all services for 160 countries including the vaccines themselves: the derived market is 8.26 times that budget and IMARC's figure 6.29 times it. Third, the only listed pure-play in the sector, Cryoport, reported total 2025 revenue of $176.2 million, which is 4.3% of the smaller published market and 0.38% of the larger, with its growth coming from cell and gene therapy rather than vaccines - corroborating the COVID-normalisation reading behind the 0.85% logistics rate. These are plausibility tests, not market estimates. They rule the logistics-only reading in as a measure of moving doses and establish that the larger figures are defensible only as equipment plus packaging plus services, which is what the publisher we follow discloses that it counts. The $46.35 billion figure is our own multiplication of a whole-market total by a stated product share and is not a published number. Separately, IMARC's own series fails its own arithmetic: 35.3 x 1.0703^9 = 65.01 against a published 66.3 billion, and the endpoint implies 7.26% against a stated 7.03%, so we publish the stated rate and not the stated endpoint.

11

Strategic Takeaways

Establish the scope before using any vaccine cold chain figure

equipment plus packaging plus services is roughly 8.5x the logistics-only reading, and the two are published under names a reader cannot distinguish

UNICEF's annual report is the most useful document in this market - 2.787 billion doses and $5.610 billion of total procurement for 2024 - because it converts any market size claim into a cost per dose you can sanity-check

A cold chain cost above a few dollars per dose should be rejected on its face for routine immunisation, since the vaccine inside the box is itself priced in cents to a few dollars

Read a 10% growth rate for healthcare cold chain as a statement about cell and gene therapy, not vaccines

Cryoport's 2025 growth came from a 29% rise in commercial cell and gene therapy support

When a publisher's stated CAGR and stated endpoint disagree, as IMARC's do by 0.23 points here, prefer the rate and say so - the endpoint is usually the rounded model output

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.